Biotech | October 26, 2021
Biological E to receive US $ 50 million to boost Covid-19 vaccine capacity
Support from DFC will help produce one billion vaccine doses by the end of 2022
Support from DFC will help produce one billion vaccine doses by the end of 2022
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Express Scripts, a leading pharmacy benefit management organization, will list Viatris labelled biosimilar insulin Glargine as a preferred insulin brand on its National Preferred Formulary (NPF)
The division is expected to grow to over a 100-member strong team by 2022
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Subscribe To Our Newsletter & Stay Updated
